Propanc Biopharma, Inc.
PPCB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $21 | $48 | $24 | $0 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $0 | $2 | $1 | $1 |
| Enterprise Value | $21 | $50 | $25 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | 50% | – | – |
| EBITDA | -$2 | -$4 | -$54 | -$0 |
| % Margin | – | -12,746.4% | – | – |
| Net Income | -$5 | -$4 | -$54 | -$0 |
| % Margin | – | -13,615.1% | – | – |
| EPS Diluted | -0.39 | -0.35 | -12.5 | -32.22 |
| % Growth | -11.4% | 97.2% | 61.2% | – |
| Operating Cash Flow | -$2 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$2 | -$0 | -$0 | -$0 |